SKY-0515

Huntington's disease

Manufacturer: Skyhawk Therapeutics
Regulatory submission: TGA provisional approval application submitted March 2026
Launch: Anticipated as early as 2027, market not specified
Last updated: October 1, 2026

Section

Product information and disease description Product description

Product information

72 evidence topics · 33 sources

Generic, brand name and therapeutic class of product3 evidence topics · 3 sources
Dosage forms and strengths5 evidence topics · 4 sources
American hospital formulary service (AHFS), or other drug classification1 evidence topic · 1 source
Indication2 evidence topics · 2 sources
Pharmacology15 evidence topics · 10 sources
Contraindications/Warnings/Precautions/Adverse effects3 evidence topics · 3 sources
Special populations4 evidence topics · 3 sources
Drug/Drug, drug/disease interactions1 evidence topic · 1 source
Dosing and administration6 evidence topics · 5 sources
Access and distribution3 evidence topics · 3 sources
Co-prescribed/Concomitant therapies4 evidence topics · 3 sources
Effect of SKY-0515 on quality measures1 evidence topic · 1 source
Product comparison24 evidence topics · 20 sources

Average sales price and wholesale acquisition cost

Product price and anticipated annual cost per participant

Not applicable.